In a pilot experiment, we sought to evaluate whether BC loaded with anti-CTLA-4 antibodies can efficiently inhibit tumor growth in the MC38 colon cancer model, which is sensitive to CTLA-4 therapy. Here, CTLA4 is linked to colonic neoplasm.